Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Coluracetam

Plain-language summaryIntrigue 50 / 100

Coluracetam is a quinoline-fused racetam developed by BrainCells Inc. for major depressive disorder. It enhances high-affinity choline uptake. Phase 2 trials were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

42/100

Mechanistically distinct racetam with failed AD trials and thin human signal outside preclinical cholinergic work

Look, coluracetam is one of the more interesting racetams on a pure mechanism basis, and we want to be fair to that before explaining why 42 is still the right number. Most racetams get credited with AMPA positive modulation and some vague neuroprotection story. Coluracetam does have the AMPA angle, but the thing that actually distinguishes it is high-affinity choline uptake enhancement. CHT1 is the rate-limiting transporter for acetylcholine biosynthesis, and hitting it upstream is a fundamentally different lever than the acetylcholinesterase inhibition that defines donepezil and galantamine. The Murai et al. AF64A cholinotoxin rodent data from the mid-90s is genuinely compelling: dose-dependent restoration of hippocampal HACU activity, normalized ACh synthesis, and cognitive improvements that outlast the compound’s plasma half-life. That last part is interesting. It suggests a durable change in CHT1 expression or trafficking rather than a simple pharmacodynamic on/off effect, and thats a real research question worth chasing.

The problem is that this interesting preclinical picture ran into a Phase 2 wall for Alzheimer’s disease at Mitsubishi Tanabe. The trial failed to hit primary efficacy endpoints. BrainCells, Inc. in-licensed and repositioned toward major depressive disorder with comorbid generalized anxiety disorder, which is a legitimately novel clinical angle for a cholinergic compound, but the evidence from that program is early, not broadly replicated, and the company hasn’t advanced it to late-stage trials. So we have strong preclinical, one failed Phase 2, and a live-but-unproven repositioning hypothesis. That evidence profile lands squarely in the 30-40 range on quality.

Translational signal is the other drag. The human signal for HACU modulation as a cognitive or antidepressant mechanism is simply not there in any robust form. Plausible? Yes. Demonstrated in people? Not convincingly. We think the MDD/GAD angle is worth watching precisely because the cholinergic-mood hypothesis has real biological traction, and hitting it through the synthesis side rather than AChE inhibition is genuinely differentiated. But watching is not the same as validated.

Where coluracetam earns real credit is bench value. If you’re studying CHT1 biology, cholinergic neurotransmission upstream of synaptic release, or trying to dissect HACU from muscarinic or AChE-dependent effects, coluracetam is one of the cleaner tools available. It won’t give you tremor or salivation at working concentrations, the selectivity for cholinergically lesioned tissue over intact tissue is a useful property for pathway dissection, and the long-duration effect after washout creates experimental opportunities that transient pharmacodynamic tools don’t. That probe utility bumps the bench value score to 50.

Honestly, coluracetam is a compound that deserves more rigorous human investigation than it’s gotten, but that’s a different claim than saying it currently has the evidence to justify high research priority. We’d put it on a watch list for investigators studying cholinergic contributions to mood or upstream ACh regulation, but we wouldn’t deprioritize better-supported compounds to get here first.

Novelty

40

Mechanism promise

50

In-category differentiation

45

Evidence quality

35

Translational signal

30

Research bench value

50

Rationale Coluracetam earns credit for a genuinely distinct primary mechanism (CHT1/HACU modulation rather than direct receptor agonism) and real bench utility as an upstream cholinergic probe, but its Phase 2 failure in AD and sparse replicated human evidence for MDD/GAD drag translational and evidence scores into the basement. It sits meaningfully above piracetam on novelty and differentiation but nowhere near compounds with live clinical programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

2-Pyrrolidinone-based racetam nootropic and high-affinity choline uptake enhancer

A synthetic racetam derivative developed at Mitsubishi Tanabe Pharma as a high-affinity choline uptake enhancer for Alzheimer’s disease, subsequently repositioned for major depressive disorder with comorbid generalized anxiety disorder, and distinguished from other racetams by a primary mechanism of action centered on choline transporter modulation rather than direct receptor agonism.

Abstract

Coluracetam (MKC-231, BCI-540) is a synthetic nootropic compound of the racetam structural class, characterized by a 2-oxopyrrolidinylacetamide pharmacophore fused to a tetrahydrofuroquinoline ring system, and distinguished from other racetam-class agents (piracetam, aniracetam, pramiracetam, oxiracetam) by a primary mechanism of action centered on the enhancement of high-affinity choline uptake (HACU), the rate-limiting step in acetylcholine biosynthesis. The compound was synthesized at the Mitsubishi Tanabe Pharma Corporation in the early 1990s as part of a medicinal chemistry program targeting cholinergic neurotransmission deficits in Alzheimer’s disease. Preclinical characterization in the ethylcholine aziridinium (AF64A) cholinotoxin rat model demonstrated that oral administration of MKC-231 at 0.3 to 10 mg/kg produced dose-dependent restoration of hippocampal high-affinity choline uptake activity, normalization of acetylcholine synthesis and release in hippocampal synaptosomes, and long-lasting cognitive improvement in Morris water maze and Y-maze paradigms that persisted beyond the elimination of the compound from plasma, suggesting a durable regulatory change in choline transporter (CHT1) expression or trafficking rather than a transient pharmacodynamic effect [1, 2, 3]. The Murai et al. (1994) study in ethylcholine aziridinium-treated mice provided the initial demonstration that MKC-231 ameliorated working memory deficits and restored hippocampal acetylcholine levels without producing the tremor, salivation, or hypothermia characteristic of direct cholinomimetic agents such as tacrine [4]. The compound advanced through Phase 2 clinical trials at Mitsubishi Tanabe for Alzheimer’s disease but failed to meet primary efficacy endpoints, and development for that indication was discontinued.

In 2006, BrainCells, Inc. in-licensed coluracetam under the designation BCI-540 and repositioned it for major depressive disorder (MDD) with comorbid generalized anxiety disorder (GAD). A Phase 2a randomized, double-blind, placebo-controlled trial in 101 evaluable patients with treatment-resistant MDD (defined as failure of an average of two prior antidepressant trials) reported no statistically significant benefit of BCI-540 at 80 mg once daily or three times daily over placebo in the overall population at six weeks on either the Hamilton Rating Scale for Depression (HAM-D) or the Hamilton Rating Scale for Anxiety (HAM-A). However, a pre-specified subgroup analysis in patients with comorbid MDD and GAD demonstrated a 12.2-point improvement on the HAM-D in the three-times-daily dosing cohort compared to 5.5 points in the placebo group (p < 0.008), and a corresponding improvement in anxiety symptoms [5]. The compound was well tolerated in this trial, with a side-effect profile similar to placebo. BrainCells, Inc. subsequently ceased active operations, and no further clinical trials have been reported.

Beyond the cholinergic mechanism, coluracetam has been characterized as a positive modulator of AMPA-type glutamate receptors (an “ampakine” property shared with aniracetam and some other racetams), though this activity is less well characterized than the HACU enhancement and the functional contribution to the in vivo pharmacology is uncertain [6]. The compound is not approved by any regulatory authority for any indication. It is supplied as a research-grade preparation by multiple chemical suppliers and is used in nootropic research contexts. Investigators should obtain analytical confirmation of identity and purity on every lot. This monograph reviews the chemistry, synthesis, and structural class of coluracetam; the HACU enhancement mechanism and supporting molecular pharmacology; the pharmacokinetic profile; the preclinical evidence base in cholinergic deficit models; the clinical evidence from the Phase 2a MDD/GAD trial; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events; and a comparative assessment of five racetam and cholinergic nootropic alternatives against coluracetam on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1432Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
Hexarelin

Plain-language summaryIntrigue 60 / 100

Hexarelin is a 6-amino-acid ghrelin receptor agonist with the most potent growth hormone-releasing effect of the GHRP family per milligram. Used in cardiology research for cardioprotective effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

53/100

Dual-receptor GHRP with a genuine cardiac angle that the class otherwise lacks, but the key discoveries are two decades old

Hexarelin is the GHRP the class kept but never fully figured out what to do with. Most people encounter it as the “most potent” growth hormone secretagogue in the peptide family, which is technically accurate but also somewhat beside the point. Raw GH output isn’t where the interesting research sits anymore. What makes hexarelin worth keeping in the conversation is the CD36 receptor story, and that’s genuinely unusual pharmacology for a hexapeptide.

Here’s the thing: CD36 is a class B scavenger receptor expressed on cardiomyocytes and macrophages that has nothing obvious to do with the hypothalamic-pituitary axis. When Deghenghi’s group and subsequently Ghigo’s team in Turin showed that hexarelin’s cardioprotective effects in ischemic preconditioning models persisted even after hypophysectomy, that was a real mechanistic finding. Multi-lab preclinical work confirmed the anti-fibrotic and some anti-atherogenic observations. No other GHRP-class compound has that pharmacology. Ipamorelin doesn’t. GHRP-2 doesn’t. Ghrelin itself binds CD36 with much lower affinity. So if your research program touches CD36-mediated cardiac biology and you want a small-molecule peptide tool, hexarelin is one of the better handles you have.

What we don’t like is the timing problem. The compound was developed in 1990, the CD36 story broke in the late 1990s to early 2000s, and the human cardiac evidence has stayed thin ever since. Preliminary human cardiovascular work showed some signal, but the large mechanistic trial that would have cemented hexarelin as a cardiac research compound never materialized. The tachyphylaxis issue compounded that: GHS-R1a desensitizes faster with hexarelin than with ipamorelin, which complicates chronic dosing protocols and limits how you can structure experiments. For the GH axis specifically, most investigators have migrated to ipamorelin (cleaner profile, less desensitization) or MK-677 (oral bioavailability), so hexarelin has lost ground as a default GH secretagogue tool.

As a bench probe, hexarelin still earns its place in specific contexts. The ipamorelin vs. hexarelin side-by-side design is actually useful if you want to parse out GH-dependent from GH-independent effects in a cardiovascular model. Thats a real experimental design that the literature has used productively. The evidence base is also better than most research peptides: multi-center clinical work on neuroendocrine endpoints, replicated preclinical cardiac data, and a plausible mechanism with some human confirmation. It’s not single-lab Bulgarian preclinical with no follow-up.

Where we land: hexarelin is an established compound with a genuinely interesting second mechanism that the rest of its class lacks. The cardiac angle keeps it relevant. But two decades have passed since the key discoveries, the clinical development pathway stalled, and the metabolic research space has shifted decisively toward incretins and mitochondrial peptides. A score in the low-to-mid 50s reflects a compound that serious investigators should know about and occasionally reach for, but not one they should be building a program around unless CD36 biology is specifically the target.

Novelty

40

Mechanism promise

62

In-category differentiation

58

Evidence quality

50

Translational signal

48

Research bench value

62

Rationale Hexarelin scores above typical GHRPs because the CD36-mediated cardioprotective mechanism is real, multi-lab confirmed, and GH-independent, giving it a meaningful research hook ipamorelin and GHRP-6 simply don’t have. What holds it back is age: the core pharmacology was established in the 1990s-2000s, tachyphylaxis limits chronic-use protocols, and the cardiac translational story never delivered the human evidence to match the preclinical signal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic hexapeptide growth hormone secretagogue receptor agonist with CD36-mediated cardioprotective activity

A synthetic hexapeptide derived from GHRP-6, developed by Mediolanum Farmaceutici as a potent growth hormone secretagogue acting through dual GHS-R1a and CD36 receptor pathways, distinguished from other growth hormone releasing peptides by pronounced cardioprotective activity independent of growth hormone release.

Abstract

Hexarelin (examorelin; His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2; CAS 140703-51-1; molecular weight 887.04 g/mol) is a synthetic hexapeptide growth hormone secretagogue developed in the early 1990s by Romano Deghenghi and colleagues at Europeptides (subsequently Mediolanum Farmaceutici) as a chemically stabilized analog of growth hormone releasing peptide-6 (GHRP-6). The compound acts through two pharmacologically distinct receptor systems: the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein-coupled receptor expressed predominantly in the hypothalamic-pituitary axis that mediates potent, dose-dependent growth hormone release; and CD36, a class B scavenger receptor expressed on cardiomyocytes, macrophages, and endothelial cells that mediates cardioprotective, anti-fibrotic, and anti-atherogenic effects independent of growth hormone secretion. The dual-receptor pharmacology distinguishes hexarelin from both the endogenous ligand ghrelin and from the more selective growth hormone secretagogue ipamorelin, and provides the molecular basis for a research literature that extends substantially beyond the neuroendocrine indication for which the compound was originally developed.

The growth hormone releasing activity of hexarelin was first characterized in humans by Ghigo, Arvat, and colleagues in 1994, who demonstrated dose-dependent GH release after intravenous, subcutaneous, intranasal, and oral administration in healthy volunteers, with subcutaneous bioavailability of approximately 77 percent, intranasal bioavailability of approximately 5 percent, and oral bioavailability of approximately 0.3 percent [1]. At an intravenous dose of 1 microgram per kilogram, hexarelin produced a GH response approximately twice that of equimolar growth hormone releasing hormone (GHRH), and co-administration with GHRH produced synergistic GH elevation described as “massive” even at low hexarelin doses [1, 2]. The compound reached Phase II clinical trials for the diagnosis and treatment of growth hormone deficiency and for congestive heart failure but was never marketed, principally owing to tachyphylaxis of the GH-releasing response on repeated daily dosing, with GH output declining by 50 to 80 percent within two to four weeks of continuous administration [3, 4].

The cardiovascular pharmacology of hexarelin represents the most pharmacologically distinctive aspect of the compound. Bhatt et al. (2002) and Bhargava et al. (2004) established that the cardioprotective effects of hexarelin in ischemia-reperfusion models are mediated through CD36 rather than GHS-R1a, using knockout mouse experiments that demonstrated abolition of cardioprotection in CD36-null animals while the effect was preserved in GHS-R1a-null animals [5, 6]. In isolated perfused rat hearts subjected to 30 minutes of ischemia followed by 120 minutes of reperfusion, hexarelin at 1 micromolar reduced infarct size by approximately 25 to 40 percent [7]. The CD36-mediated signaling involves activation of peroxisome proliferator-activated receptor gamma (PPARgamma), phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) survival pathways, and suppression of pro-apoptotic caspase-3 activity [8, 9]. In spontaneously hypertensive rats, five weeks of hexarelin treatment significantly reduced cardiac fibrosis by decreasing interstitial and perivascular collagen deposition, reducing collagen I and III expression, and attenuating left ventricular hypertrophy [10]. Human clinical studies have demonstrated acute positive inotropic effects: in healthy volunteers, hexarelin increased left ventricular ejection fraction from 64.0 to 70.7 percent within 15 to 30 minutes of intravenous administration, and in patients with coronary artery disease undergoing bypass surgery, hexarelin produced prompt increases in left ventricular ejection fraction, cardiac index, and cardiac output lasting up to 90 minutes [11, 12].

Beyond the cardiovascular system, hexarelin has demonstrated neuroprotective activity in preclinical models. In a rat model of neonatal hypoxia-ischemia, hexarelin reduced brain damage by 39 percent in the cerebral cortex, hippocampus, and thalamus through Akt/glycogen synthase kinase-3-beta phosphorylation and caspase-3 suppression [13]. In neuroblastoma cell lines, hexarelin modulated MAPK and PI3K/Akt pathways to inhibit hydrogen peroxide-induced apoptotic toxicity [14].

Pharmacokinetically, hexarelin has a plasma elimination half-life of approximately 55 to 70 minutes in humans after parenteral administration. The compound is administered predominantly by subcutaneous injection at research doses of 1 to 2 micrograms per kilogram (approximately 100 to 300 micrograms per administration in adults). Principal adverse effects are dose-dependent and include transient flushing, mild cortisol and prolactin elevation (more pronounced than ipamorelin but less clinically significant than early reports suggested), increased appetite, and water retention. The cortisol and prolactin elevations reflect direct GHS-R1a activation on corticotroph and lactotroph cells and are the principal pharmacodynamic distinction from the more selective secretagogue ipamorelin. No galactorrhea, Cushingoid features, or clinically significant endocrine adverse events have been reported in any published hexarelin study. This monograph documents the chemistry and synthesis, dual-receptor pharmacology, comprehensive pharmacokinetics, the clinical and preclinical evidence base across neuroendocrine, cardiovascular, and neuroprotective applications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a structured comparative assessment of five growth hormone secretagogue candidates against hexarelin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1455Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
Fasoracetam

Plain-language summaryIntrigue 48 / 100

Fasoracetam is a cyclohexyl-carbonyl racetam developed for ADHD with the mGluR1 mechanism. Phase 2 trials by Aevi Medical did not reach approval. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

46/100

A mechanistically distinct racetam with real mGluR pharmacogenomics signal, but a compromised translational record

Look, fasoracetam is one of those racetams that actually has something going on beneath the surface, and thats worth acknowledging before we explain why it still only lands in the mid-40s.

The mechanism is genuinely unusual for its class. Most racetams are AMPA modulators or choline uptake facilitators. Fasoracetam does the cholinergic thing too, but adds two layers you don’t normally see from this structural family: repeated administration upregulates GABA-B receptors in the cerebral cortex (Oguchi et al. 1998, Nippon Shinyaku), which is a direction most GABA-B-active compounds don’t go, and Maeda et al. (1997) characterized pan-mGluR modulation spanning all three receptor groups. Group I through Group III. That’s mechanistically distinct from anything else in the racetam family, and it’s the reason this compound earned a second life at all. If your program touches mGluR biology or receptor upregulation dynamics in cortical circuits, fasoracetam is a more interesting tool than piracetam, pramiracetam, or most of the standard HACU-focused options.

Here’s the problem: the compound is from 1986, the Phase 3 program for vascular dementia failed to hit statistical significance on cognitive endpoints, and the most recent at-scale development effort, Avalo Therapeutics after its chain of acquisitions from NeuroFix through Aevi Genomic Medicine, was deprioritized following disappointing efficacy results when the study population broadened beyond the pharmacogenomically selected cohort. That’s a failed Phase 3 and a failed scale-up against you before you even look at the data quality.

What we do find genuinely interesting is the Elia et al. 2018 Nature Communications study. Thirty adolescents with ADHD harboring mutations in mGluR network genes were treated with NFC-1, and both CGI and Vanderbilt scores improved significantly. This is precision medicine logic applied to a racetam, and the reasoning is defensible: if mGluR network dysfunction is the mechanism you’re targeting, then a compound with pan-mGluR activity is actually the right probe to reach for. The evidence is thin (n=30, open-label, single-blind), but the mechanistic coherence is real. Nobias Therapeutics is now applying this same logic in 22q11.2 deletion syndrome, which is arguably an even better-defined model for glutamatergic dysfunction research.

So where does that leave the bench investigator? Fasoracetam earns its place in a library if the program involves mGluR biology, GABA-B receptor regulation, or neurodevelopmental disease models with a glutamatergic component. It’s not a first-line tool and it’s not indispensable. Sourcing is solid across multiple chemical suppliers, though enantiomeric verification matters; the (5R) isomer is the active form and the racemic mixture meaningfully dilutes potency. We don’t think this belongs at the top of anyone’s queue right now, but as a niche probe in a pharmacogenomics-adjacent program, it earns a library slot at mid-tier priority.

Novelty

40

Mechanism promise

62

In-category differentiation

48

Evidence quality

32

Translational signal

38

Research bench value

52

Rationale The pan-mGluR plus GABA-B receptor upregulation profile is genuinely unusual for a racetam and provides real probe value in glutamatergic and neurodevelopmental research; the Elia 2018 pharmacogenomic stratification study is the strongest modern hook. But the vascular dementia Phase 3 failure, 30-patient ADHD signal, and Avalo’s deprioritization after scale disappointment pull down evidence quality and translational confidence, landing the compound firmly in the mid-40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pyrrolidone-class racetam nootropic with GABA-B receptor upregulation, metabotropic glutamate receptor modulation, and cholinergic enhancement activity

A synthetic pyrrolidone nootropic developed at Nippon Shinyaku as a cognition enhancer for vascular dementia, distinguished from other racetams by GABA-B receptor upregulation, metabotropic glutamate receptor activation across all three mGluR groups, and facilitation of high-affinity choline uptake in the cerebral cortex and hippocampus.

Abstract

Fasoracetam (NS-105, NFC-1, LAM-105) is a synthetic nootropic of the racetam family, defined structurally as (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one and distinguished from the canonical racetam piracetam by the substitution of a piperidine amide at the 5-position of the 2-pyrrolidinone ring. The compound was synthesized at Nippon Shinyaku Co., Ltd. in the mid-1980s and advanced through Phase 3 clinical trials in Japan for vascular dementia, an indication in which it failed to demonstrate statistically significant efficacy on cognitive endpoints and was subsequently abandoned by the originator. The pharmacological profile comprises three principal mechanisms: upregulation of gamma-aminobutyric acid type B (GABA-B) receptors in the cerebral cortex following repeated administration; activation of metabotropic glutamate receptors (mGluRs) across all three receptor groups (Group I, Group II, and Group III); and facilitation of cholinergic neurotransmission through enhanced high-affinity choline uptake and increased acetylcholine release from cortical and hippocampal neurons. These mechanisms were characterized in a series of rat studies conducted at Nippon Shinyaku during the 1990s, with the GABA-B upregulation and learned helplessness reversal reported by Oguchi et al. (1998), the cholinergic facilitation and anti-amnestic activity reported by Maeda et al. (1997), and the involvement of both cholinergic and GABAergic systems in memory disruption reversal confirmed by Ito et al. (1999). Preclinical pharmacology demonstrates reversal of scopolamine-induced amnesia in passive avoidance and radial arm maze paradigms, reversal of baclofen-induced amnesia, reduction of immobility time in the forced swimming test, and rescue of escape failure in the learned helplessness paradigm, with minimum effective doses as low as 0.1 mg/kg intraperitoneally for the active (5R) enantiomer. The compound was repurposed for attention deficit hyperactivity disorder (ADHD) following its acquisition by NeuroFix, Inc., which obtained the Nippon Shinyaku clinical data package and advanced the compound under the designation NFC-1. A five-week open-label, single-blind, placebo-controlled Phase 1/2 study in 30 adolescents with ADHD harboring mutations in mGluR network genes (Elia et al. 2018, Nature Communications) reported significant improvement on Clinical Global Impressions scales and parental Vanderbilt Assessment scores, with dose-proportional pharmacokinetics across the 50 to 800 mg dose range, a plasma elimination half-life of approximately 4 to 7 hours, rapid oral absorption with peak plasma concentrations at 1.3 to 1.9 hours, and oral bioavailability of 79 to 97 percent. The compound undergoes minimal hepatic metabolism and is excreted predominantly unchanged through the kidneys. There were no differences in adverse event incidence between placebo and active treatment weeks. Despite the ADHD pharmacogenomic signal, subsequent development has not produced a registration-enabling efficacy demonstration. NeuroFix was acquired by Medgenics (later Aevi Genomic Medicine, later Avalo Therapeutics), and development of fasoracetam for ADHD was deprioritized following disappointing efficacy results at scale. As of the most recent monograph revision, fasoracetam is under Phase 2 investigation by Nobias Therapeutics for 22q11.2 deletion syndrome (DiGeorge syndrome). The compound is not approved by any regulatory authority worldwide and is not marketed as a medicine. It is available as a research-grade preparation from multiple chemical suppliers. Investigators should obtain analytical confirmation of identity, purity, and enantiomeric configuration on every lot, as the (5R) enantiomer is the active isomer and the racemic mixture has reduced potency.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1431Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
Nefiracetam

Plain-language summaryIntrigue 45 / 100

Nefiracetam is a dimethylphenyl racetam developed in Japan for cognitive impairment. Trials in post-stroke depression and apathy showed modest effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

46/100

A pharmacologically rich racetam probe with multi-target hippocampal mechanism and a stalled clinical record

Look, nefiracetam is one of those compounds that looks exciting on paper and ends up being a teachable case in how mechanistic complexity doesn’t automatically translate to clinical success. Developed by Daiichi Pharmaceutical in Japan during the 1980s as DM-9384, it’s the most pharmacologically characterized fat-soluble member of the racetam class, and thats not a trivial distinction. The compound engages GABA-A receptors at nanomolar affinity (IC50 ~8.5 nM for [3H]muscimol displacement), potentiates neuronal nicotinic acetylcholine receptors through a PKC-coupled G-protein pathway, enhances L-type and N-type voltage-gated calcium channel currents, and potentiates NMDA receptor function by reducing the Mg2+ block via PKC activation. The downstream convergence of those effects on hippocampal LTP through CaM kinase II and PKC alpha is genuinely interesting biology, and it distinguishes nefiracetam from every other racetam in a way that’s mechanistically meaningful rather than incidental.

What we like here: the mechanism is real, well-characterized, and multi-target in a way that isn’t just polypharmacology noise. The Nishizaki and Yoshii labs did thorough preclinical work across the 1990s and 2000s, and the signaling cascade from presynaptic nicotinic receptor activation to glutamate release to NMDA potentiation to LTP is experimentally supported in rodent hippocampal slice preparations with decent rigor. The poststroke apathy work is the most credible clinical signal in the human record. That’s a legitimately hard indication, and the signal, however modest, was real enough to sustain a serious clinical program.

Here’s the thing though: the drug had multiple clinical programs spanning cerebrovascular dementia, Alzheimer’s disease, poststroke depression, and poststroke apathy, and it came out of all of them without an approval. Translon never launched commercially. The US Alzheimer’s trial trajectory didn’t demonstrate sufficient efficacy to move forward. That doesn’t invalidate the preclinical mechanistic story, but it tells you the translational arrow isn’t strong, and in 2026 we can’t pretend the clinical record looks any better than it did when the programs closed.

The novelty case is simply weak at this point. This is 1980s chemistry derived from the piracetam scaffold. Investigators working in cognitive pharmacology have newer, more targeted tools available. Where nefiracetam retains real value is as a probe compound for the GABA-A/nAChR/NMDA convergence question specifically, and for studies that need a racetam with documented calcium channel effects and a known PKC-dependent LTP readout. That bench utility is real and it’s not well-covered by alternatives in the class. We’d reach for this over standard piracetam in any protocol where the calcium channel or PKC-dependent LTP angle matters. We wouldn’t prioritize it over more recent mechanism-targeted tools for the same questions. The 46 reflects a compound worth having in a serious catalog, but not one driving anyone’s primary research agenda right now.

Novelty

30

Mechanism promise

62

In-category differentiation

48

Evidence quality

45

Translational signal

40

Research bench value

55

Rationale Nefiracetam sits well above the racetam baseline because its convergent GABA-A/nAChR/NMDA/VGCC mechanism via PKC and CaMKII is genuinely interesting and preclinically well-characterized; however, 1980s compound age, no commercial approval after multiple clinical programs, and a weak translational arrow pull the overall into the mid-40s range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Fat-soluble pyrrolidinone racetam nootropic with multi-target modulation of GABAergic, cholinergic, and glutamatergic neurotransmission

A lipophilic 2-oxopyrrolidinyl acetamide derived from the piracetam scaffold, developed by Daiichi Pharmaceutical as an antiamnesic agent for cerebrovascular dementia and distinguished from other racetams by concurrent modulation of GABA-A receptors, neuronal nicotinic acetylcholine receptors, voltage-gated calcium channels, and NMDA receptor function through convergent protein kinase C and CaM kinase II signaling.

Abstract

Nefiracetam (DM-9384, Translon), the N-(2,6-dimethylphenyl) acetamide derivative of 2-oxopyrrolidine and the most pharmacologically characterized fat-soluble member of the racetam nootropic class, is a cognition-enhancing agent developed by Daiichi Pharmaceutical (now Daiichi Sankyo) in Japan during the 1980s for the treatment of cognitive impairment secondary to cerebrovascular disease. Unlike the parent compound piracetam, which acts principally through membrane fluidity modulation and non-specific cholinergic facilitation, nefiracetam engages a convergent set of molecular targets: high-affinity interaction with the GABA-A receptor chloride channel complex (IC50 approximately 8.5 nM for displacement of [3H]muscimol binding), potentiation of neuronal nicotinic acetylcholine receptor currents through a G-protein-coupled protein kinase C pathway, enhancement of voltage-gated L-type and N-type calcium channel currents, potentiation of NMDA receptor function via protein kinase C activation with consequent reduction of the voltage-dependent magnesium block, and facilitation of hippocampal long-term potentiation through CaM kinase II and protein kinase C alpha activation downstream of NMDA receptor and metabotropic glutamate receptor 5 stimulation. The composite pharmacology produces a sustained facilitation of hippocampal synaptic transmission that resembles long-term potentiation and that depends on presynaptic nicotinic acetylcholine receptor activation and consequent glutamate release.

Pharmacokinetics in healthy human volunteers are characterized by rapid oral absorption with peak plasma concentrations at approximately 1 to 2 hours, monophasic elimination with a plasma half-life of 3 to 5 hours, linear dose-proportional kinetics across the 100 to 900 mg range, negligible accumulation on repeated dosing, and principal hepatic metabolism through CYP3A4-mediated 5-hydroxylation of the pyrrolidine ring with a minor contribution from CYP1A2. Less than 10 percent of the administered dose is excreted unchanged in urine. The compound crosses the blood-brain barrier readily owing to its lipophilicity relative to piracetam.

The clinical development program encompassed three principal indications. In cerebrovascular dementia, Phase 2 and Phase 3 trials conducted in Japan by Daiichi demonstrated cognitive improvement in patients with sequelae of cerebral infarction; however, a revised Phase 3 trial failed to meet its primary endpoint, and the New Drug Application was withdrawn in Japan in February 2002. In Alzheimer’s disease, the National Institute of Neurological Disorders and Stroke sponsored a randomized, double-blind, placebo-controlled Phase 2 trial (NCT00001933) evaluating nefiracetam at 600 mg and 900 mg daily for 20 weeks; preliminary reports indicated dose-dependent cognitive improvement in a subset of patients, but the program was not advanced to Phase 3. In poststroke depression and apathy, Robinson et al. (2008, 2009) conducted randomized controlled trials demonstrating that nefiracetam at 900 mg daily produced significant reduction in apathy scores in poststroke depressed patients, though the primary depression endpoint was not met; a subsequent confirmatory trial by Starkstein et al. (2016) for poststroke apathy did not replicate the benefit, possibly owing to insufficient statistical power.

The compound is not approved in any jurisdiction as of the current monograph date. It is available as a research-grade preparation from multiple chemical suppliers. The principal preclinical toxicology concern is species-specific nephrotoxicity observed in dogs and rats attributable to a metabolite (M-18) that is not formed in humans or primates; long-term studies in humans and primates have not identified renal toxicity. This monograph reviews the chemistry, synthesis, and structural positioning of nefiracetam; the multi-target molecular pharmacology in mechanistic detail; the human pharmacokinetic record; the preclinical pharmacology across cognitive, anticonvulsant, and neuroprotective models; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a structured comparative assessment of five racetam-class nootropics against nefiracetam on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1433Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
CDP-Choline

Our opinion on this compoundEstablished workhorse

43/100

Solid neuroprotective probe with layered mechanism, but major RCTs failed its primary thesis

Look, CDP-choline has a story that starts promisingly and ends with two very large negative trials. The ICTUS study (Dávalos et al., 2012, roughly 2,000 patients) was the definitive test for acute ischemic stroke. It missed. COBRIT missed for TBI. Those arent small wrinkles, thats the whole translational thesis the compound was built on. Acknowledging that upfront is the only honest way to position this in a research context.

What keeps CDP-choline above the piracetam tier is the mechanism story, which is genuinely more layered than its OTC supplement reputation suggests. The compound delivers two independent substrates: choline, which feeds acetylcholine synthesis and Kennedy-pathway phosphatidylcholine assembly; and cytidine, which converts in human plasma to uridine, a pyrimidine that signals through P2Y receptors and potentiates nerve growth factor. Alpha-GPC delivers choline more efficiently on a molar basis, but it doesn’t bring cytidine. That dual-substrate architecture, plus the dopaminergic modulation angle via D2 receptor upregulation, makes CDP-choline more interesting as a pharmacological tool than simple choline sources. The Kennedy-pathway rate-limiting step, CTP:phosphocholine cytidylyltransferase, is a real handle for investigators working in neural membrane biophysics.

We think the more interesting territory now is outside stroke and TBI entirely. The cocaine-craving literature is small but consistent: Renshaw et al. (1999) and subsequent confirmatory work show real signal on craving scores, and the mechanism traces through dopaminergic normalization in a way that’s preclinically coherent. The glaucoma angle, specifically retinal ganglion cell preservation, produced positive Phase 2 data (Ottobelli et al., 2012 and successors). Neither indication has big-RCT backing yet, but the effect sizes are more plausible than what stroke trials were chasing. These are live research questions with few competing tools.

Honestly, the compound is better than its nootropics-forum reputation and worse than its 1990s neuroprotection hype. For bench investigators, the dual-substrate delivery is useful for dissecting which component, choline or cytidine/uridine, is driving an observed effect in membrane dynamics or cholinergic signaling. That’s real probe value, but it’s not indispensable in the way a receptor-specific ligand is. What we don’t like is that the evidence base is large and messy: a century of European phase trials with heterogeneous endpoints, two decisive negative large-scale RCTs, and a handful of smaller positives in narrower populations. The compound hasn’t lost relevance, but it’s reached the plateau of its primary thesis, and the frontier investigators have largely moved on to more tractable targets.

Novelty

22

Mechanism promise

45

In-category differentiation

42

Evidence quality

62

Translational signal

46

Research bench value

52

Rationale CDP-choline sits above piracetam on the evidence ladder due to multi-mechanism architecture and genuine clinical trial volume, but ICTUS and COBRIT fatally undermined the stroke and TBI translational case; substance dependence and glaucoma are real secondary signals that prevent full relegation, but novelty is near zero for a 1956-identified endogenous intermediate marketed in 60+ countries.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous cytidine nucleotide intermediate in the Kennedy pathway of phosphatidylcholine biosynthesis with cholinergic, membranotropic, and neuroprotective activity

An endogenous pyrophosphate-linked cytidine-choline conjugate that serves as the obligate intermediate in the de novo biosynthesis of phosphatidylcholine, administered exogenously as a neuroprotective and procognitive agent across stroke, traumatic brain injury, and age-related cognitive decline indications.

Abstract

Cytidine 5′-diphosphocholine (CDP-choline, citicoline) is an endogenous mononucleotide composed of cytidine and choline linked by a diphosphate bridge, functioning as the direct and obligate precursor to phosphatidylcholine in the Kennedy pathway of membrane phospholipid biosynthesis first characterized by Eugene P. Kennedy and Samuel B. Weiss in 1956. Exogenous administration of CDP-choline supplies the central nervous system with both choline (the substrate for acetylcholine synthesis and for phosphatidylcholine assembly) and cytidine (which is converted in human plasma to uridine, a pyrimidine nucleoside involved in synaptic glycoprotein synthesis and in the potentiation of nerve growth factor signaling). Oral bioavailability exceeds 90 percent in humans, and the compound is rapidly hydrolyzed in the intestinal wall and liver to its two circulating components, cytidine and choline, which cross the blood-brain barrier independently and are reassembled intracellularly by CTP:phosphocholine cytidylyltransferase, the rate-limiting enzyme of the Kennedy pathway. The pharmacological profile encompasses membrane phospholipid restoration, acetylcholine augmentation, dopaminergic modulation, attenuation of phospholipase A2-mediated arachidonic acid release, and preservation of cardiolipin and sphingomyelin content in ischemic neural tissue. These mechanisms collectively support the neuroprotective activity demonstrated in rodent models of focal and global cerebral ischemia, traumatic brain injury, and excitotoxic neuronal death.

The clinical evidence base for CDP-choline spans more than 11,000 patients across multiple indications. In acute ischemic stroke, the compound was studied in the International Citicoline Trial on Acute Stroke (ICTUS), a 2,298-patient randomized, double-blind, placebo-controlled trial that produced a neutral primary endpoint (global recovery odds ratio 1.03, 95 percent confidence interval 0.86 to 1.25) but demonstrated benefit in prespecified subgroups including patients older than 70 years and those with less severe baseline deficits. An independent meta-analysis of ten randomized controlled trials subsequently reported a pooled odds ratio of 1.56 (95 percent confidence interval 1.12 to 2.16) favoring independence with citicoline treatment. In traumatic brain injury, the Citicoline Brain Injury Treatment Trial (COBRIT), a 1,213-patient Phase 3 trial published by Zafonte et al. in JAMA (2012), did not demonstrate benefit on functional or cognitive status at 90 days. In age-related cognitive impairment, a 2021 randomized controlled trial demonstrated significant improvement in episodic memory in healthy older adults after 12 weeks of oral supplementation at 500 mg daily. In chronic cerebrovascular disease, Cochrane meta-analysis identified positive short-term effects on memory and behavior, though evidence was limited by study duration and heterogeneity. The compound is registered as a pharmaceutical agent in over 60 countries for neurological indications (marketed as Somazina, Recognan, Ceraxon, and numerous generics) and is classified as a dietary supplement in the United States, where it has received Generally Recognized as Safe (GRAS) status. The toxicological profile is favorable: the oral LD50 in rats exceeds 2,000 mg/kg, no serious adverse events have been attributed to the compound in controlled trials, and adverse event rates in meta-analyses are comparable to placebo. This monograph reviews the chemistry, biosynthetic role, and stereochemistry of CDP-choline; the multitarget neuroprotective and cholinergic pharmacology; the complete pharmacokinetic record including the cytidine-to-uridine conversion unique to primates; the clinical evidence base across stroke, traumatic brain injury, cognitive impairment, glaucoma, and substance dependence indications; sourcing, reconstitution, and quality verification; stack interactions; adverse events and safety; and a comparative assessment of five alternative choline-pathway or membrane-trophic agents against CDP-choline on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1444Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
Pentadeca Arginate

Our opinion on this compoundSingle-lab provenance

45/100

BPC-157 arginate salt improves oral bioavailability but inherits a single-lab evidence problem

Look, the case for Pentadeca Arginate starts with a genuinely interesting formulation problem. BPC-157 as the acetate salt falls apart under gastric acid. Less than 2 percent structural integrity after five hours of simulated gastric exposure. The arginate salt fixes that, delivering greater than 95 percent stability under the same conditions and a reported 7-fold oral bioavailability advantage over the acetate form. For a peptide research program that cares about oral dosing, thats meaningful. The L-arginine counterion also contributes NOS-substrate activity that complements the parent peptide’s established nitric oxide axis pharmacology in a way that feels purposeful rather than incidental.

The underlying BPC-157 pharmacology is genuinely interesting. The mechanism involves bidirectional NO modulation through Akt-eNOS signaling, VEGFR2 and EGFR upregulation, ERK1/2-driven fibroblast proliferation, and early response gene cascades (Egr1, Akt1, Src, Nos3) that activate within minutes of tissue injury. We find the multi-pathway cytoprotection story compelling as a research question. The fact that a single 15-amino acid peptide from human gastric juice apparently coordinates wound healing, GI protection, angiogenesis, and neuroprotection across multiple organ systems is precisely the kind of pleiotropic biology that deserves rigorous investigation.

Here’s the problem: rigorous investigation hasn’t happened. The BPC-157 literature runs to over 100 publications, but the vast majority originate from a single group at the University of Zagreb, predominantly the Sikiric lab. Independent multi-center replication is essentially absent. For Pentadeca Arginate specifically, the evidence base is even thinner. The 7x bioavailability figure comes from limited PK characterization; human pharmacokinetic data remain extremely limited, and the oral advantage in humans has not been independently validated. The clinical database for BPC-157 encompasses fewer than 30 total participants across all human studies combined. Three pilot trials. That’s the entire human evidence base for a compound with an outsized reputation in research communities.

The FDA’s 2023 Category 2 classification for BPC-157 in compounding pharmacy contexts is relevant for any investigator thinking about sourcing continuity. Pentadeca Arginate emerged partly as a response to that designation, which is worth naming directly rather than eliding. The preclinical PK data from Xu et al. 2022 also shows a short plasma elimination half-life of approximately 15 minutes in rats, which has implications for study design that dont always appear in the community discussion of this compound.

What we actually like here is the formulation chemistry. The arginate salt design is a real innovation over the acetate form for oral delivery studies, and if the underlying BPC-157 biology is going to be seriously investigated, PDA is the better oral research tool. What we don’t like is that the entire enterprise still rests on a single-lab evidence base that has resisted independent replication for three decades. The score reflects where the evidence actually is, not where the community has collectively decided it must be.

Novelty

45

Mechanism promise

58

In-category differentiation

58

Evidence quality

22

Translational signal

30

Research bench value

50

Rationale PDA’s arginate formulation is a genuine innovation over BPC-157 acetate for oral delivery, but the underlying evidence base is dominated by the single Zagreb consortium with no meaningful independent replication, and PDA-specific human data is nearly nonexistent. Novelty and differentiation scores reflect the formulation advance; evidence and translational scores reflect the unchanged single-lab reality.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Arginate salt of the stable gastric pentadecapeptide BPC-157, a cytoprotective and tissue-regenerative 15-amino-acid oligopeptide

An arginine-salt formulation of the gastric pentadecapeptide BPC-157 (Body Protection Compound-157) developed to improve oral bioavailability and acid stability, retaining the parent peptide’s pleiotropic cytoprotective, angiogenic, and tissue-regenerative pharmacology across gastrointestinal, musculoskeletal, and central nervous system research models.

Abstract

Pentadeca Arginate (PDA) is the arginate salt form of the stable gastric pentadecapeptide BPC-157 (Body Protection Compound-157, bepecin, PL 14736), a synthetic 15-amino-acid oligopeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of 1419.55 daltons (free base). The parent peptide was first characterized by Sikiric and colleagues at the University of Zagreb in 1993 as a partial sequence of a protein isolated from human gastric juice, and it has since accumulated a preclinical literature of more than 100 peer-reviewed publications demonstrating cytoprotective, pro-angiogenic, anti-inflammatory, and tissue-regenerative activity across gastrointestinal, musculoskeletal, hepatic, cardiovascular, and central nervous system injury models. The arginate salt formulation replaces the conventional acetate counterion with L-arginine, producing two pharmacologically consequential changes: first, a marked improvement in structural stability under simulated gastric acid conditions (greater than 95 percent structural integrity after five hours of gastric acid exposure, compared to less than 2 percent for the acetate form); and second, a reported increase in oral bioavailability of approximately 7-fold relative to the acetate salt, attributed to the arginine shielding of the peptide backbone from enzymatic degradation and the concurrent delivery of L-arginine as a nitric oxide synthase substrate that complements the parent peptide’s established nitric oxide system modulation. The pharmacology of Pentadeca Arginate is that of BPC-157, a pleiotropic cytoprotective agent whose principal characterized mechanisms include bidirectional modulation of nitric oxide production through the Akt-eNOS signaling axis; upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), epidermal growth factor receptor (EGFR), and growth hormone receptor expression; activation of extracellular signal-regulated kinase (ERK1/2) pathways driving fibroblast proliferation and collagen deposition; modulation of dopaminergic, serotonergic, and GABAergic neurotransmitter systems; and activation of early response gene cascades (Egr1, Akt1, Src, Nos3) within minutes of tissue injury. Preclinical pharmacokinetic characterization in rats and beagle dogs (Xu et al. 2022) demonstrated rapid absorption after intramuscular administration (Tmax approximately 3 minutes in rats, 6 to 9 minutes in dogs), a short plasma elimination half-life (approximately 15 minutes in rats, approximately 5 minutes in dogs), linear pharmacokinetics across studied dose ranges, and rapid metabolism to constituent amino acids through normal peptide degradation pathways. Human pharmacokinetic data remain extremely limited. Clinical evidence for BPC-157 in humans is confined to three pilot studies encompassing fewer than 30 total participants: a Phase I safety study in healthy volunteers (Veljaca et al. 2003), a Phase II enema study in ulcerative colitis (Ruenzi et al., unpublished full data), and recent intravenous safety studies (Lee and Burgess 2024, Lee et al. 2025) that reported no adverse events or clinically meaningful changes in cardiac, hepatic, renal, thyroid, or metabolic biomarkers at doses up to 20 mg. BPC-157 is not approved by any drug regulatory agency for human use. In September 2023, the United States Food and Drug Administration classified BPC-157 as a Category 2 bulk drug substance, prohibiting its use in compounding by 503A and 503B pharmacies. The World Anti-Doping Agency banned BPC-157 in 2022 under the S0 category of non-exempt substances. Pentadeca Arginate emerged in the clinical and compounding pharmacy market as an alternative formulation following the FDA Category 2 classification, leveraging the arginate salt distinction. This monograph reviews the chemistry, synthesis, and salt-form pharmacology of Pentadeca Arginate; the comprehensive preclinical pharmacology of the parent BPC-157 peptide across gastrointestinal, musculoskeletal, vascular, and central nervous system models; the limited human clinical evidence; sourcing and quality considerations; reconstitution and handling; stack-interaction implications; the adverse-event and safety profile; and a comparative assessment of five tissue-regenerative peptide candidates against Pentadeca Arginate on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1452Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
Choline Bitartrate

Plain-language summaryIntrigue 40 / 100

Choline bitartrate is a basic salt form of choline used as a dietary choline supplement. It is the cheapest form of supplemental choline but with lower bioavailability than alpha-GPC or CDP-choline for brain delivery. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

21/100

The cheapest and least brain-penetrant choline form, outperformed by alternatives on every research-relevant metric

Look, choline bitartrate is as basic as choline delivery gets. It’s the tartrate salt form that makes up roughly 41% choline by mass, and it’s everywhere in commerce specifically because it’s cheap and water-soluble. That’s genuinely it. The research question isn’t “does choline matter” – it does, and the NIH and UNC deprivation studies made that definitive decades ago – the question is whether choline bitartrate is interesting as a research compound, and the answer is pretty clearly no.

The mechanism story is entirely mature. Choline feeds acetylcholine synthesis via choline acetyltransferase, enters the Kennedy pathway to make phosphatidylcholine, and gets oxidized to betaine for one-carbon methyl donation. All three arms are textbook biochemistry from the 1970s and 1980s. Theres nothing here that a serious bench scientist hasnt seen a hundred times, and the novelty ceiling is essentially zero.

What makes this particularly awkward as a library candidate is that choline bitartrate is explicitly outperformed by its alternatives on the dimensions that matter for research. Alpha-GPC and CDP-choline penetrate the blood-brain barrier meaningfully; choline bitartrate mostly doesn’t. Phospholipid-conjugated choline sources produce higher incremental phosphatidylcholine enrichment in plasma. And choline bitartrate produces substantially more trimethylamine N-oxide than its competitors – which isn’t just a metabolic loss pathway, it’s an active cardiovascular risk signal confirmed in prospective cohort data. So we’re looking at a compound that’s the slowest, least brain-available, and potentially most atherogenic choline form on the market. That’s a bad profile for any serious research program.

The clinical evidence is where it gets complicated, but not complicated in an interesting way. Placebo-controlled supplementation trials in healthy young adults have failed to show meaningful cognitive enhancement; the visuomotor and pupil constriction signals that have been reported are not the stuff of a compelling research program. The positive signal comes from deficiency correction – real and important, but nutritional science, not frontier pharmacology. The gestational data is legitimate and the NAFLD connection has real epidemiological support, but both of those point to choline broadly, not this specific salt form.

We think the fair read here is that choline bitartrate is a useful ingredient in population-level nutritional research and in deficiency-model work, but as a probe for cholinergic function or cognitive biology, its the wrong tool. Investigators who want to study choline’s CNS effects use alpha-GPC or CDP-choline. Investigators studying the TMAO pathway would actually find the bitartrate form relevant precisely because it’s a reliable TMAO generator – but thats a narrow and somewhat perverse niche. The compound belongs in the catalog as a comparator reference, not as a frontier target worth anyone’s bench time.

Novelty

12

Mechanism promise

18

In-category differentiation

12

Evidence quality

38

Translational signal

30

Research bench value

25

Rationale Choline bitartrate scores low across all axes because it represents a fully mature, textbook mechanism in the most inferior delivery form available: lower BBB penetration, higher TMAO output, and less phosphatidylcholine enrichment than every meaningful alternative. Supplementation trials in healthy adults have failed on cognitive endpoints; the real signal is deficiency correction, which is nutritional science, not frontier biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Quaternary ammonium salt delivering the essential nutrient choline as a bitartrate conjugate for acetylcholine precursor loading, phospholipid biosynthesis, and methyl-group donation

A water-soluble tartaric acid salt of the essential nutrient choline, widely used as a dietary supplement to support acetylcholine synthesis, hepatic lipid export, and one-carbon methylation metabolism, distinguished from other choline donors by low cost, high aqueous solubility, and moderate oral bioavailability but limited blood-brain barrier penetration relative to phospholipid-conjugated choline sources.

Abstract

Choline bitartrate is the tartaric acid salt of choline, a quaternary ammonium compound recognized as an essential nutrient by the United States Institute of Medicine in 1998. The salt form contains approximately 41 percent choline by mass and is the most widely manufactured and least expensive choline supplement form in global commerce. Choline itself is a precursor to acetylcholine (synthesized by choline acetyltransferase from choline and acetyl-coenzyme A), to the membrane phospholipid phosphatidylcholine (synthesized by the cytidine diphosphate-choline or Kennedy pathway), and to the methyl donor betaine (synthesized by choline dehydrogenase and betaine aldehyde dehydrogenase in a two-step mitochondrial oxidation), which donates methyl groups to homocysteine in the betaine-homocysteine methyltransferase reaction. These three metabolic fates underwrite a broad physiological role that spans neurotransmission, membrane structural integrity, hepatic very-low-density lipoprotein assembly, one-carbon metabolism, and epigenetic regulation of gene expression through histone and DNA methylation. Pharmacokinetic studies in healthy volunteers demonstrate rapid oral absorption with peak plasma choline concentrations achieved within one to two hours after ingestion of a single dose. However, choline bitartrate delivers choline as the free water-soluble cation, which is subject to substantial first-pass hepatic extraction and gut microbial conversion to trimethylamine before systemic distribution. Gut microbial trimethylamine production and subsequent hepatic flavin-containing monooxygenase 3 oxidation to trimethylamine N-oxide represent both a metabolic loss pathway and a potential cardiovascular risk signal, as elevated circulating trimethylamine N-oxide concentrations have been associated with increased atherosclerotic cardiovascular disease incidence in prospective cohort studies. Compared to phospholipid-conjugated choline sources (alpha-glycerophosphocholine, cytidine diphosphate-choline, phosphatidylcholine from egg yolk or krill oil), choline bitartrate produces higher peak trimethylamine N-oxide levels and lower incremental phosphatidylcholine enrichment in plasma, reflecting differential metabolic routing. The clinical evidence base for choline bitartrate as a standalone supplement is mixed. Controlled feeding studies at the National Institutes of Health and at the University of North Carolina have established that dietary choline deprivation produces hepatic steatosis, elevated serum aminotransferase, and muscle damage in both men and women within weeks, confirming essentiality in humans. Epidemiological studies link higher dietary choline intake to reduced risk of nonalcoholic fatty liver disease and to reduced neural tube defect incidence in offspring of pregnant women. However, placebo-controlled trials of acute choline bitartrate supplementation in healthy young adults have failed to demonstrate significant enhancement of declarative memory or working memory, although improvements in visuomotor performance and pupil constriction have been reported. Chronic supplementation data in rodent models show cognitive and locomotor improvements accompanied by reduced oxidative stress. The evidence is more favorable for cognitive benefit in elderly populations and in individuals with diagnosed choline deficiency, consistent with the compound functioning as a conditional nootropic whose benefit depends on baseline choline status. The Institute of Medicine established Adequate Intake values of 550 mg per day for adult men and 425 mg per day for adult women, with 450 mg per day during pregnancy and 550 mg per day during lactation. The Tolerable Upper Intake Level for adults is 3500 mg of choline per day; adverse effects above the upper limit include hypotension, fishy body odor (from trimethylamine excretion), sweating, gastrointestinal distress, and hepatotoxicity. Population surveys indicate that the majority of adults in North America and Europe consume choline below the Adequate Intake, and fewer than 10 percent of pregnant women meet gestational requirements. This monograph reviews the chemistry, synthesis, and salt-form characteristics of choline bitartrate; the three-arm molecular pharmacology (acetylcholine synthesis, phospholipid biosynthesis, methyl donation); comprehensive pharmacokinetics including the trimethylamine N-oxide pathway; the clinical evidence base across cognitive, hepatic, gestational, and cardiovascular endpoints; sourcing and quality verification; reconstitution and handling; stack interactions with other cholinergic, nootropic, and hepatoprotective agents; adverse events and safety signals including the trimethylamine N-oxide cardiovascular association; and a comparative assessment of five alternative choline-delivery compounds (alpha-glycerophosphocholine, cytidine diphosphate-choline, phosphatidylcholine, choline chloride, and centrophenoxine) against choline bitartrate on five competency standards (bioavailability and brain penetration, effect size on cognitive endpoints, breadth of clinical evidence, side-effect profile, and cost-effectiveness).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1448Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
Phenylpiracetam

Plain-language summaryIntrigue 65 / 100

Phenylpiracetam (Phenotropil) is a piracetam molecule with a phenyl group bolted onto the ring, which gives it a stimulant edge that the parent racetam lacks. Developed in Russia in the 1980s and used there for stroke recovery, asthenia, and post-traumatic cognitive decline, it nudges dopamine and norepinephrine release while also tweaking AMPA glutamate receptors. Users report focus and physical drive at low doses; tolerance builds quickly. The World Anti-Doping Agency banned it in sport because of its athletic performance signal. Russian clinical trials are reasonably extensive but rarely independently replicated in the West, and there are no FDA-quality studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

Multi-mechanism racetam with enantiomer-resolved DAT pharmacology and real stimulant effects, let down by regionally siloed clinical evidence

Look, phenylpiracetam is not a flashy modern compound. It’s from 1983, developed at the Institute of Biomedical Problems for Soviet cosmonauts, and the main clinical literature is in Russian. But dismissing it as just another racetam would be a mistake, because the pharmacological story that’s emerged from the Latvian Institute of Organic Synthesis over the last decade and a half is genuinely interesting and has real implications for how we think about monoaminergic nootropics.

The parent compound, piracetam, has essentially no meaningful interaction with dopaminergic or nicotinic systems. Phenylpiracetam does. The phenyl group at C-4 confers increased lipophilicity and opens up a substantially broader pharmacological profile: AMPA positive allosteric modulation (shared with the racetam class), binding to alpha-4-beta-2 nicotinic acetylcholine receptors at an IC50 of roughly 5.86 micromolar, and dopamine transporter inhibition that is both stereoselective and enantiomer-divergent. That last part is what we think is the most scientifically interesting element here.

Zvejniece and Dambrova’s 2017 work resolved the enantiomers and found genuinely different pharmacology. The (R)-form is a dual norepinephrine-dopamine reuptake inhibitor carrying the bulk of the psychostimulant and procognitive activity. The (S)-form is selectively DAT-inhibiting, reduces body weight gain in Zucker rat and diet-induced obesity models, and does this without the locomotor stimulation you’d expect from a typical monoamine reuptake blocker. Thats a useful pharmacological dissociation that makes the (S)-enantiomer a legitimately interesting probe for separating anti-obesity DAT pharmacology from stimulant liability. Merz Pharmaceuticals thought so too; they’ve filed patents on (R)-phenylpiracetam specifically for Parkinson’s disease and sleep disorders under the code MRZ-9547.

The clinical evidence is the weak point. It exists, and it’s not trivial: a 12-month post-stroke trial in roughly 400 patients, a 30-day TBI and surgical cognition study in 99 patients, adjunctive epilepsy data. But this is Russian-language work of moderate methodological rigor, and none of it has been meaningfully replicated in Western RCT infrastructure. The WADA prohibited-list entry since 1998 is probably the most credible independent signal that the stimulant activity is real, given the detection in doping control at the 1997 World Athletics Championships.

What limits the score here is the combination of an evidence base thats geographically siloed and methodologically uneven, a compound old enough to lose significant novelty credit, and an indication space where it competes directly with modafinil and other agents that have far better trial records. The enantiomer pharmacology is interesting enough that we’d expect more Western bench work to follow, particularly around the (S)-enantiomer’s selective DAT profile. Until that replication happens, phenylpiracetam sits in a productive but frustrating middle ground: more interesting mechanistically than its racetam siblings, less validated than its stimulant comparators.

Novelty

40

Mechanism promise

62

In-category differentiation

60

Evidence quality

38

Translational signal

48

Research bench value

52

Rationale The enantiomer-divergent dopamine transporter pharmacology from Zvejniece and Dambrova, and the (S)-enantiomer’s selective DAT inhibition without locomotor stimulation, are the genuinely interesting research angles that separate this from its racetam siblings; however, evidence is real but confined to Russian clinical infrastructure with no meaningful Western replication, and the compound’s 1983 origin limits novelty despite the recent mechanistic refinement.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Racetam-class nootropic and psychostimulant with dopamine transporter inhibition, nicotinic acetylcholine receptor modulation, and AMPA receptor positive allosteric modulation

A 4-phenyl derivative of piracetam developed at the Russian Institute of Biomedical Problems as a cosmonaut performance enhancer, distinguished from the parent racetam by stereoselective dopamine transporter inhibition, enhanced blood-brain barrier penetration, psychostimulant activity, and a broader pharmacological profile spanning cognition, neuroprotection, cold tolerance, and anti-inflammatory effects.

Abstract

Phenylpiracetam (fonturacetam, INN; carphedon; 4-phenylpiracetam) is a racetam-class nootropic and psychostimulant first described by Bobkov et al. in 1983 and developed at the Institute of Biomedical Problems of the Russian Academy of Sciences for the enhancement of cognitive, physical, and thermoregulatory performance in cosmonauts operating under conditions of sustained stress, microgravity, and cold exposure. The compound is the 4-phenyl-substituted analog of piracetam and was approved for medical use in Russia in 2003 under the trade name Phenotropil for indications including cerebrovascular insufficiency, cognitive decline following stroke or traumatic brain injury, depression, asthenia, and attentional disorders. Phenylpiracetam is approximately 20- to 60-fold more potent than piracetam in animal models of cognition and anticonvulsant activity, an enhancement attributed to the phenyl substituent conferring increased lipophilicity, improved blood-brain barrier penetration, and direct engagement with monoaminergic and glutamatergic receptor systems that the parent compound does not meaningfully occupy. The molecular pharmacology of phenylpiracetam has been substantially clarified by the work of Zvejniece, Dambrova, and colleagues at the Latvian Institute of Organic Synthesis, who demonstrated in 2011 that the racemic compound binds the alpha-4-beta-2 subtype of the nicotinic acetylcholine receptor with an IC50 of 5.86 micromolar, and in 2017 that the individual enantiomers exhibit divergent dopamine transporter (DAT) pharmacology: (R)-phenylpiracetam is a dual norepinephrine-dopamine reuptake inhibitor with an IC50 at DAT of approximately 14.5 micromolar and 11-fold lower affinity for the norepinephrine transporter, while (S)-phenylpiracetam is a selective DAT inhibitor that reduces body weight gain in obese Zucker rats and diet-induced obesity models without producing the locomotor stimulation characteristic of the (R)-enantiomer [1, 2]. The (R)-enantiomer is the more pharmacologically active form for psychostimulant and procognitive effects and is the subject of independent patent filings for Parkinson disease, sleep disorders, and disease-associated fatigue. Both enantiomers additionally modulate AMPA-type glutamate receptors through positive allosteric modulation, consistent with the broader racetam class mechanism, and contribute to neuroprotective and anti-inflammatory activity demonstrated in lipopolysaccharide and carrageenan inflammation models [3]. Pharmacokinetics in humans are characterized by rapid oral absorption with near-complete bioavailability, a time to maximum plasma concentration of approximately one hour, a plasma elimination half-life of three to five hours, and negligible hepatic metabolism: the compound is excreted essentially unchanged, with approximately 40 percent recovered in urine and 60 percent in bile and sweat. The absence of cytochrome P450 involvement eliminates the polymorphic pharmacokinetic variability that complicates other nootropic and psychostimulant agents and reduces drug-drug interaction liability. Clinical evidence is derived predominantly from Russian-language trials of moderate methodological rigor. A 12-month study in approximately 400 post-stroke patients demonstrated enhanced recovery of neurological function and cognitive performance relative to standard rehabilitation. A 30-day trial in 99 patients with cognitive deficits secondary to surgery or traumatic brain injury reported significant improvements in motor coordination, memory, attention, and higher brain function at 200 mg daily. An adjunctive epilepsy trial reported seizure frequency reduction and cognitive benefit. The compound has been on the World Anti-Doping Agency Prohibited List since 1998 as a stimulant (class S6), following detection in athlete doping control samples at the 1997 World Athletics Championships. This monograph reviews the chemistry, synthesis, and stereochemistry of phenylpiracetam; the dopaminergic, nicotinic, and glutamatergic receptor pharmacology with enantiomer-resolved detail; human pharmacokinetics; the preclinical and clinical evidence base across cognitive, neuroprotective, anti-inflammatory, metabolic, and physical performance domains; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a comparative assessment of five alternative nootropic and procognitive compounds against phenylpiracetam on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1428Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
Adrafinil

Plain-language summaryIntrigue 50 / 100

Adrafinil is the original eugeroic that the body converts to modafinil in the liver. It was sold in France as Olmifon for elderly daytime alertness before being discontinued in 2011. It is sold today as a research chemical because it is unscheduled in most jurisdictions. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

25/100

A prodrug of modafinil with no independent pharmacological identity and a weak clinical record ended by regulatory withdrawal

Adrafinil is the original eugeroic, and that historical note is about the most interesting thing you can say about it in a research context today. Developed by Laboratoire Lafon in the 1970s and marketed as Olmifon in France from 1986, it was always a transitional compound: the prodrug from which modafinil was isolated and independently developed. Once modafinil exists, adrafinil’s independent research value collapses almost entirely.

The pharmacology story here is straightforward to the point of being limiting. Adrafinil is hepatically converted to modafinil via hydrolysis of the terminal hydroxamic acid moiety. The active species is modafinil. The mechanism of interest, atypical DAT inhibition driving downstream orexinergic and histaminergic activation, belongs to modafinil. Studying adrafinil’s mechanism means studying its prodrug conversion and then studying modafinil. There’s nothing unique at the pharmacology bench that adrafinil reveals about wakefulness biology that you can’t get more cleanly from modafinil directly.

The clinical evidence base is genuinely thin. Six French studies, conducted between 1979 and the mid-1990s in mostly elderly patients, reported improvements in vigilance, attention, and affective scores. But these trials used outcome measures and sample sizes that don’t meet modern evidentiary standards, and the compound’s 2011 withdrawal by the French Commission d’AMM came with an explicit finding that clinical evidence was insufficient to establish benefit. That’s a damning regulatory conclusion. Modafinil went through actual Phase 3 trials, received FDA approval in 1998, and wins on every dimension: cleaner pharmacokinetics, no prodrug conversion overhead, far stronger evidence, and a fully characterized regulatory profile.

What we don’t like is the hepatotoxicity signal. Chronic use elevates hepatic enzymes, and rare but serious skin reactions have been reported. For a compound with no pharmacological advantage over modafinil, this adds meaningful safety liability to any prolonged animal study design. thats a genuine constraint even in pure RUO contexts, where you’re already choosing the inferior probe.

The one real argument for adrafinil is regulatory access. It’s unscheduled in the US, UK, Canada, and most other jurisdictions, while modafinil carries Schedule IV status in the United States. If a program genuinely needs a wakefulness-promoting probe and faces institutional barriers to Schedule IV compounds, adrafinil provides a pathway. That’s real, if narrow. But it’s a workaround argument, not a scientific one, and it doesn’t change what you’re actually putting in the animal.

We think the compound belongs in the library for historical completeness and for researchers in that specific access scenario. As an active research priority in 2026, though, it earns no enthusiasm. Better tools exist, and the evidence base for adrafinil itself doesn’t justify the hepatic tradeoff.

Novelty

20

Mechanism promise

35

In-category differentiation

15

Evidence quality

22

Translational signal

35

Research bench value

25

Rationale Adrafinil’s score is governed almost entirely by its status as a transitional prodrug: all pharmacological interest belongs to modafinil, the clinical evidence base is pre-modern and was found insufficient by regulatory determination in 2011, differentiation against modafinil is near-zero across every competency standard, and hepatotoxicity adds liability without compensating benefit. The narrow unscheduled-access use case earns modest bench value credit but cannot rescue the overall.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Diphenylmethyl sulfinyl acetamide eugeroic; prodrug of modafinil with wakefulness-promoting activity

A benzhydryl sulfinyl hydroxamic acid developed at Laboratoire Lafon as a vigilance-promoting agent for elderly patients, distinguished from classical psychostimulants by its prodrug relationship to modafinil and by a wakefulness mechanism mediated principally through atypical dopamine transporter inhibition and downstream orexinergic, histaminergic, and glutamatergic activation.

Abstract

Adrafinil (CRL-40028, Olmifon) is a synthetic diphenylmethyl sulfinyl hydroxamic acid compound and the first clinically introduced member of the eugeroic (wakefulness-promoting) pharmacological class, marketed in France from 1986 to 2011 for the treatment of inattention, drowsiness, and vigilance deficits in elderly patients. The compound functions as a prodrug: hepatic metabolism converts adrafinil to its primary active metabolite modafinil (CRL-40476, 2-diphenylmethylsulfinylacetamide), which was subsequently developed independently and received regulatory approval in the United States (1998), the European Union, and more than 20 additional jurisdictions for the treatment of narcolepsy, obstructive sleep apnea-associated excessive daytime sleepiness, and shift work sleep disorder. The prodrug conversion proceeds through enzymatic hydrolysis of the terminal hydroxamic acid to yield modafinil, with concurrent production of the inactive metabolite modafinilic acid (CRL-40467). The pharmacological activity of adrafinil is therefore substantially attributable to modafinil, an atypical dopamine reuptake inhibitor that binds the dopamine transporter (DAT) with low micromolar affinity (Ki approximately 2.3 micromolar) and produces wake-promoting effects through a cascade involving elevated extracellular dopamine, activation of D1 and D2 dopamine receptors, downstream stimulation of lateral hypothalamic orexin (hypocretin) neurons, secondary activation of tuberomammillary histaminergic projections, and modulation of cortical glutamatergic and GABAergic tone. Positron emission tomography studies in humans have demonstrated that modafinil at clinical doses occupies approximately 50 to 57 percent of striatal dopamine transporters, an occupancy level comparable to methylphenidate, though modafinil produces substantially less reinforcing subjective effects and lower abuse liability than classical psychostimulants. Clinical evidence for adrafinil itself is confined to six principal studies conducted in France between 1979 and the mid-1990s, predominantly in ambulatory and hospitalized elderly patients (aged 45 years and older, majority older than 65 years) exhibiting vigilance, attention, memory, and affective complaints. These studies reported improvements in attention, wakefulness, self-evaluated vigilance, depressive symptom scores, and functional autonomy, though the trial designs, outcome measures, and sample sizes did not meet the evidentiary standards that would later govern modafinil registration. The compound was voluntarily withdrawn from the French market in September 2011 following a regulatory review by the Commission d’Autorisation de Mise sur le Marche that concluded the clinical evidence was insufficient to establish benefit and that the known adverse effect profile, including hepatic enzyme elevations with chronic use and rare skin reactions, constituted an unfavorable risk-benefit ratio given the availability of modafinil as a more potent, better characterized, and directly acting alternative. Adrafinil is not a controlled substance in the United States, the United Kingdom, Canada, or most other jurisdictions, and is sold as an unregulated research compound and dietary supplement. This monograph reviews the chemistry, synthesis, and stereochemistry of adrafinil; the prodrug conversion and the molecular pharmacology of its active metabolite modafinil; the pharmacokinetic profile including hepatic biotransformation; the preclinical pharmacology in rodent, feline, and primate models; the clinical evidence base across vigilance, narcolepsy, and cognitive endpoints; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal including hepatotoxicity; and a structured comparative assessment of five wakefulness-promoting alternatives against adrafinil on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1437Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026
Phosphatidylcholine

Plain-language summaryIntrigue 50 / 100

Phosphatidylcholine is the most abundant phospholipid in cell membranes. Supplementation supports liver function (a long-standing use in liver disease) and cellular membrane health. It also serves as a choline source for the brain. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

36/100

Fundamental membrane phospholipid with established hepatic use but minimal novelty or frontier research appeal

Look, phosphatidylcholine is one of the most important molecules in eukaryotic biology and simultaneously one of the least compelling objects of fresh investigation for a research library like this. It constitutes 40 to 60 percent of total membrane phospholipid mass in mammalian cells, it’s the principal choline donor for acetylcholine synthesis, and the Kennedy CDP-choline pathway that produces it was fully characterized in the 1950s and 60s. That’s not a criticism. That’s just what it is: finished biology.

The hepatoprotective angle via essential phospholipid preparations, sold commercially as Essentiale and related products, is where PC has its most credible clinical footprint. The EPL preparations standardized to high-DLPC fractions carry regulatory approval across more than 50 jurisdictions, and the hepatic mechanism, involving membrane restitution and modulation of phospholipase A2 activity in injured hepatocytes, is well understood and replicated. But this is a 1970s pharmaceutical story. We aren’t scoring research excitement for being right a long time ago.

The differentiation picture is genuinely weak. For cholinergic research, citicoline and alpha-GPC both offer more targeted CNS delivery of the choline moiety, and the literature consistently treats them as preferred tools over bulk PC for anything neurological. For membrane biology, researchers working on specific lipid species use POPC or DPPC or PAPC directly rather than a mixed PC fraction. The compound-as-class problem is real here: what gets sold as phosphatidylcholine in supplement and reagent contexts is a heterogeneous mixture, which makes reproducibility harder and the signal-to-noise worse than investigators would want.

What we do credit is bench utility in certain niche contexts. DPPC is indispensable for pulmonary surfactant modeling. Pure PC molecular species are essential components for liposome and lipid nanoparticle formulation research, which is an active and growing field. The phospholipase A2 and DAG-mediated signaling literature still uses PC substrates to probe second-messenger pathways. Thats real utility, just not the kind that earns a high score here because those roles are well-established, not frontier.

The TMAO story, where gut microbiota convert choline to trimethylamine and then to cardiovascular-risk-associated TMAO, is honestly the most interesting current angle on PC biology, and even that has been in active circulation since the Hazen lab work in 2011 and 2013. Interesting biochemistry, mostly resolved science from a research standpoint. Investigators who want to study PC deeply have everything they need. That’s not what this library is for.

Novelty

18

Mechanism promise

22

In-category differentiation

30

Evidence quality

60

Translational signal

55

Research bench value

50

Rationale PC scores low on novelty and mechanism because it is foundational biochemistry, not frontier science; the Kennedy pathway, EPL hepatoprotective preparations, and choline-donation role have been mature for decades. Evidence and translational scores are relatively higher because EPL preparations carry genuine multi-jurisdictional clinical approval and replicated hepatic data, but those strengths lift a compound that is simply not an interesting research target by the standard the rubric demands. Raw weighted score of 36 sits comfortably below the foundational-metabolite ceiling of 38, so no cap binds.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Glycerophospholipid; 1,2-diacyl-sn-glycero-3-phosphocholine membrane constituent and choline donor

The predominant structural phospholipid of eukaryotic cell membranes, serving as an endogenous reservoir of choline for acetylcholine biosynthesis, a hepatoprotective agent in essential phospholipid preparations, and a substrate for phospholipase-mediated signal transduction.

Abstract

Phosphatidylcholine (PC) is the most abundant glycerophospholipid in eukaryotic cell membranes, constituting 40 to 60 percent of total membrane phospholipid mass in mammalian cells, with an even greater proportion (80 to 90 percent) in the outer leaflet of the plasma membrane. Structurally, PC consists of a glycerol backbone esterified at the sn-1 and sn-2 positions with fatty acyl chains of variable length and saturation and at the sn-3 position with a phosphocholine headgroup. Because the fatty acid composition varies by tissue source and dietary intake, PC is properly understood as a compound class rather than a single molecular entity; the predominant species in mammalian tissues include 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PAPC), and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, the principal component of pulmonary surfactant). In supplemental and pharmaceutical contexts, the term phosphatidylcholine most commonly refers to soy-derived or egg-derived lecithin fractions enriched to 40 to 96 percent PC content, with polyenylphosphatidylcholine (PPC) preparations standardized to high proportions of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) constituting the basis for the essential phospholipid (EPL) pharmaceutical class marketed as Essentiale and related products in more than 50 jurisdictions.

The biosynthesis of PC in mammalian cells proceeds through two principal pathways: the CDP-choline (Kennedy) pathway, in which dietary or recycled choline is phosphorylated by choline kinase, activated to CDP-choline by CTP:phosphocholine cytidylyltransferase (the rate-limiting enzyme), and condensed with diacylglycerol by choline phosphotransferase; and the phosphatidylethanolamine N-methyltransferase (PEMT) pathway, in which phosphatidylethanolamine undergoes three sequential methylations using S-adenosylmethionine as the methyl donor. The PEMT pathway operates principally in the liver and contributes approximately 30 percent of hepatic PC production under adequate choline intake, increasing in relative importance during dietary choline deficiency. Disruption of either pathway has been linked to fatty liver disease, lipodystrophy, and metabolic dysfunction in both animal models and human genetic studies.

As a dietary supplement and pharmaceutical agent, PC has been evaluated principally in four clinical domains: hepatoprotection (nonalcoholic fatty liver disease, alcoholic liver disease, drug-induced liver injury), cognitive function (Alzheimer disease, age-related cognitive decline), cardiovascular lipid management, and injectable lipolysis (cosmetic fat reduction). The hepatoprotective application is the most extensively studied and the most commercially significant. Essential phospholipid preparations containing 73 to 96 percent 3-sn-phosphatidylcholine have been evaluated in multiple randomized controlled trials and large observational studies, with consistent evidence of reductions in hepatic transaminase levels (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase), improvements in ultrasonographic steatosis grading, and reductions in hepatic fat content as measured by magnetic resonance spectroscopy. The 2024 EXCEL trial, a multicenter randomized double-blind placebo-controlled study, reported a 2.5-fold greater reduction in liver fat with EPL treatment compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease. Dosing in the hepatoprotective indication is typically 1,800 mg per day of EPL (equivalent to approximately 1,300 to 1,700 mg of PC) administered in three divided doses for 12 to 24 weeks.

The cognitive application has produced less favorable clinical evidence. A 2003 Cochrane systematic review of 12 randomized trials involving 376 patients with Alzheimer disease, Parkinsonian dementia, or subjective memory complaints found no clear clinical benefit of lecithin or PC supplementation on any cognitive outcome measure. The negative clinical trial findings contrast with epidemiological observations: the Framingham Heart Study offspring cohort reported that individuals in the highest quartile of dietary phosphatidylcholine intake had a 28 percent lower risk of incident dementia compared to the lowest quartile. The discrepancy likely reflects the difference between maintaining adequate choline status across a lifetime and attempting to reverse established neurodegeneration with short-term supplementation.

A significant safety consideration emerged from the 2011 and 2013 reports by Hazen and colleagues demonstrating that intestinal microbial metabolism of the choline moiety of dietary PC produces trimethylamine (TMA), which is oxidized by hepatic flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO), a metabolite associated with increased atherosclerotic burden, major adverse cardiovascular events, and mortality in large prospective cohort studies. The TMAO pathway does not represent a direct toxicity of PC but rather a diet-microbiome interaction that modulates cardiovascular risk and that should be considered in the context of high-dose, long-term PC supplementation.

This monograph reviews the chemistry, biosynthesis, and structural diversity of phosphatidylcholine; the molecular pharmacology of membrane incorporation, phospholipase-mediated signaling, choline liberation, and hepatoprotective mechanisms; pharmacokinetics of oral and parenteral administration; the preclinical pharmacology in liver, brain, and cardiovascular models; the clinical evidence base across hepatoprotective, cognitive, cardiovascular, and cosmetic indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions; adverse events and safety signals including the TMAO pathway; and a comparative assessment of five choline-donor and membrane-active compounds (citicoline, alpha-glycerylphosphorylcholine, choline bitartrate, phosphatidylserine, sphingomyelin) against phosphatidylcholine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1449Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 11, 2026

←Previous Page

1 … 22 23 24 25 26 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.